Dongsong medicine and a new class of drugs hit the impact of a surge of 900% insulin

Pharma Network January 21st, January 20th, Dongsian Pharmaceuticals two innovative drugs clinical applications were accepted by CDE contractor, respectively, 1 new drug HEC88473 injection and 3.3 new drug Degu insulin injection.
in 2020, Dongsian Pharmaceuticals has 1 new class 3.3 drug application for the market, 9 new drug applications for clinical (7 for class 1 new drugs), of which 6 have been approved for clinical.
source: CDE official heC88473 injection is the first new class 1 drug to submit a clinical application in 2021; Degu insulin injection is a new, ultra-long-effect insulin analogue,2 Global sales exceeded US$1.5 billion in 2019, and in the first half of 2020, terminal sales of urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) exceeded 50 million, up 922.6% YoY.
In the past 2020, Dongsian Pharmaceuticals has applied for a new drug to be marketed for insulin glycerine injections, according to MiNet data, in the first half of 2020 China's public medical institutions terminal insulin glycerine sales of more than 3 billion yuan.
addition, 7 new drugs of class 1 and 2 new drugs of class 2 were applied for clinical treatment, of which HEC95468 tablets, recombinant anti-VEGF humanized monoclonal antibody injection, HEC122505MsOH tablets, HEC89736PTSA.0.5H2O tablets, toluene sulphate nitrogen capsules, hydrochloric acid ionoid tablets have been approved clinically.
2020 East Sunshine Drug Innovation Drug Declaration Source: MED2.0 China Drug Review Database Class 1 New Drugs, HEC89736PTSA.0.5H2O Tablets are the mouth of Dongsian Pharmaceuticals' independent research and development Highly selective PI3K pyrethroid inhibitors intended for the treatment of blood tumors, HEC122505 MSOH tablets as neurological drugs, have been initiated phase I clinically, and toluene sulfonate nigtini capsules and hydrochloric acid ivenione tablets have not been approved for the first time clinically.
2 new drugs, recombinant anti-VEGF humanized monoclonal antibody injection for beva bead monobial-like drugs, currently has Zinda, Qilu two enterprises bio-similar drugs approved for listing.
source: Mi Net database, CDE official website note: data statistics as of January 20, if there are omissions, welcome to point out!